Biosimilars [Design Issues]

posted by Chiku – India, 2012-02-03 07:43 (4901 d 16:40 ago) – Posting: # 8043
Views: 6,813

Hi Vasu,

As far as FDA is concerned i am not able to find specific guideline for biosimiler. But from my very little experience i can say: u will require to have
1) Sameness
a) Bilogical sameness---PK/PD study either in Human or Animal model case by case basis
b) analytical sameness by Size exclusion, Elisa etc suitable method for structure elucidation depends on molecule charecteristics

2) Bioequivalence with PK end point

3) Immunogenesity if applicable


Regards

Chiku:)

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,680 registered users;
39 visitors (0 registered, 39 guests [including 11 identified bots]).
Forum time: 01:24 CEST (Europe/Vienna)

In the field of observation,
chance favors only the mind that is prepared.    Louis Pasteur

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5